文献速递血液透析通路

VasQ美国关键性研究证实外部血管支撑装置用于动静脉瘘创建的安全性和有效性

VasQ U.S. pivotal study demonstrates the safety and effectiveness of an external vascular support for arteriovenous fistula creation.
PubMed 文献 · J Vasc Surg · 2023-07-30

VasQ在美国16个中心前瞻性单臂开放标签研究中植入144例新建动静脉瘘患者,6个月一期通畅率66%,优于55%性能目标(P < .021),生理性成熟率92.4%,窃血2.1%、感染0.7%,无动脉瘤或血清肿,2年累积通畅率76.6%(95%CI 67.9%-83.4%)。

要点

  • 6个月一期通畅率66%,优于55%性能目标(P < .021)。
  • 生理性成熟率92.4%,透析患者双针穿刺成功率88%(中位56天)。
  • 窃血2.1%、感染0.7%,无动脉瘤或血清肿,2年累积通畅率76.6%。

核心结论

  • 美国关键性研究显示,VasQ相对传统动静脉瘘改善了结局并具有优良安全性。
  • 在该试验条件下,VasQ在快速高效提升动静脉瘘功能成功方面展现出很大前景。

研究设计与样本

  • 2年前瞻性、多中心、单臂、开放标签研究,在美国16个中心纳入144例拟新建动静脉瘘并同意入组患者。
  • 分析头臂动静脉瘘129例和桡头动静脉瘘15例,主要终点为6个月一期通畅率与系统文献检索衍生的55%性能目标比较。
  • 安全性终点包括至6个月装置相关事件、窃血、感染、动脉瘤和血清肿。
  • 最小动脉尺寸2.0 mm,目标静脉需测量2.5至6 mm。
  • 关键排除标准为年龄<18或>80岁、已知同侧中心静脉闭塞、目标穿刺区静脉深度大于8 mm、纽约心脏协会3或4级。

主要发现

  • 患者61%男性、53%白人、35%非裔美国人、14%西班牙裔,平均年龄60岁,体重指数中位数30.4。
  • 69%患糖尿病,66%在创建时透析,70%有既往通路手术史。
  • 6个月时窃血2.1%、感染0.7%,未见动脉瘤或血清肿。
  • 6个月一期通畅率66%(P < .021 vs 性能目标),生理性成熟率92.4%。
  • 透析入组患者双针穿刺成功率88%(中位56天),研究期间开始透析的透析前患者双针穿刺成功率81.6%。

关键数值与推荐

  • 6个月一期通畅率66%(P < .021 vs 55%性能目标)。
  • 2年累积通畅率76.6%(95%CI 67.9%-83.4%),需干预与未需干预患者间无统计学差异。
  • 头臂与桡头动静脉瘘间未观察到通畅率差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Arteriovenous fistula (AVF) creation is a commonly performed vascular operation that reports 6-month functional success rates as low as 50%. Recently, a nitinol external vascular support device, VasQ, has shown potential in studies outside the United States (U.S.) to improve AVF outcomes when implanted at creation. Here, the pivotal study results of this novel technology in treating patients in the U.S. are described. METHODS: VasQ was implanted in 144 patients at 16 centers across the U.S. who were referred for creation of a new AVF and consented for enrollment in a 2-year, prospective, multicenter, single-arm, open-label study. Brachiocephalic (n = 129) and radiocephalic (n = 15) AVFs were analyzed. The primary endpoint was primary patency at 6 months compared against a performance goal of 55% derived from a systematic literature search. Safety endpoints included device-related events, ischemic steal, infection, aneurysm, and seroma at up to 6 months. Minimum arterial size was 2.0 mm; target veins were required to measure 2.5 to 6 mm. Key exclusion criteria were patients <18 or >80 years, those with known ipsilateral central venous occlusion, target cannulation zone venous depth greater than 8 mm, and New York Heart Association class 3 or 4. RESULTS: Patients were 61% male, 53% White, 35% African American, and 14% Hispanic. Mean age was 60 years, and median body mass index was 30.4. Of the patients, 69% were diabetic, 66% were on dialysis at the time of creation, and 70% had a prior access surgery. At 6 months, steal was observed in 2.1%, infection in 0.7%, and no aneurysms or seromas were seen. Primary patency at 6 months was 66% (P < .021 vs performance goal). Physiological maturation was achieved in 92.4% of patients. Successful two-needle cannulation for patients that entered the study on dialysis was achieved in 88% of VasQ AVFs at a median of 56 days. Pre-dialysis patients who initiated dialysis during the study achieved two-needle cannulation in 81.6% VasQ AVFs. Interventions were required at a rate of 1.07 per patient year over the entire study period. Two-year cumulative patency was 76.6% (95% confidence interval, 67.9%-83.4%) with no statistical difference between patients requiring interventions and those that did not. No patency differences were observed between brachiocephalic and radiocephalic AVFs. CONCLUSIONS: The U.S. pivotal study results demonstrated improved AVF outcomes and an excellent safety profile with VasQ use relative to traditional AVFs. Under the conditions of this trial, VasQ shows great promise in expeditiously and efficiently enhancing AVF functional success.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dillavou ED, Lucas JF, Woodside K, et al. VasQ U.S. pivotal study demonstrates the safety and effectiveness of an external vascular support for arteriovenous fistula creation. J Vasc Surg. 2023. PMID: 37527689. doi:10.1016/j.jvs.2023.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。